Atlas Trials

Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

Clinical trial NCT05457829 · RECRUITING

Trial details

NCT number
NCT05457829
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Rhabdomyosarcoma, Child
Start date
2023-12-30
Primary completion
2026-06-30
Enrollment
88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.